2024 Year in Review: A Message from Our CEO

By Linh Hoang
December 23rd, 2024
HistoWiz_Stain

Dear HistoWiz Community,

As 2024 draws to a close, I want to take a moment to reflect on an incredible year for HistoWiz. This year, we achieved remarkable milestones that underscore our commitment to revolutionizing histology and digital pathology. Thanks to your trust and collaboration, HistoWiz is better positioned than ever to accelerate scientific discoveries and improve outcomes in biomedical research.

This year, we proudly launched GLP-compliant services, delivering the fastest turnaround times in the industry. Our offerings include high-quality H&E and trichrome staining, routine immunohistochemistry, and expert pathology consultations, all designed to support rigorous GLP studies with unmatched precision and speed.

Our digital pathology platform underwent a major upgrade with the release of PathologyMap 2.0. This enhanced platform introduces flexible metadata integration for seamless slide organization, lightning-fast search capabilities to locate data in milliseconds, universal image upload compatibility with major image formats, and on-platform AI analysis for efficient tissue segmentation and quality assurance.

Additionally, it provides tools for curating collections and facilitating effortless collaboration whether the images were produced by HistoWiz or by others. We also revolutionized tissue block management with the introduction of our new Block Manager service. This innovative solution offers 24-hour retrieval time without fees, integrated histology services for streamlined workflows, transparent pricing, and real-time tracking for complete control over your samples.

To further empower your research, we expanded our service portfolio with several new offerings:

  • Multiomics: Provides comprehensive insights into RNA-targeted therapeutics and protein dynamics.
  • Akoya PSP: Delivers up to six markers with rapid turnaround for key research questions.
  • CST SignalStar: Features customizable panels with industry-leading antibodies.
  • Cell IDx: Offers high-specificity panels with excellent morphology tailored to your needs.
  • Ultivue InSituPlex: Provides panels with up to 12 markers validated for clinical-grade trials.

These achievements reflect our ongoing mission to advance pathology through innovation, quality, and collaboration. None of this would have been possible without the hard work of our team and the unwavering support of our clients and partners. As we move into 2025, we remain committed to delivering cutting-edge solutions to accelerate your research.

Thank you for being an integral part of HistoWiz’s journey. We look forward to achieving even greater milestones together in the year ahead.

Warm regards,

Linh Hoang

CEO, HistoWiz